Viral conjunctivitis treatment using Ranpirnase and/or Amphinase
The present specification discloses Ranpirnase and Amphinase, compositions comprising Ranpirnase and/or Amphinase, and methods and uses to treat a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reduce or suppress a level of virus or viral titer, reduce or suppress viral replication, reduce or suppress protein synthesis, reduce or suppress a level of a tRNA, reduce or suppress a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulate or enhance a peroxisome proliferator-activated receptor (PPAR) pathway signal, promote the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reduce or suppress a NFκB pathway signal using Ranpirnase, Amphinase or compositions comprising Ranpirnase and/or Amphinase.
1. A method of treating a viral conjunctivitis in an individual in need thereof, the method comprising administering multiple times a day to a surface of a conjunctiva and/or eye of the individual a pharmaceutical composition comprising a therapeutic effective amount of at most 2 μg of one or more Ranpirnases and a pharmaceutically-acceptable vehicle,
wherein administration reduces a symptom associated with the viral conjunctivitis, thereby treating the individual.
2. The method according to claim 1 , wherein the viral conjunctivitis is an epidemic keratoconjunctivitis, a pharyngoconjunctival fever, a nonspecific sporadic follicular conjunctivitis, or a chronic papillary conjunctivitis.
3. The method according to claim 1 , wherein the viral conjunctivitis is cause by a Human adenovirus B, a Human adenovirus D, a Human adenovirus E or any combination thereof.
4. The method according to claim 3 , wherein the Human adenovirus B is a Human adenovirus B serotype 3, a Human adenovirus B serotype 7, a Human adenovirus B serotype 11, or any combination thereof.
5. The method according to claim 3 , wherein the Human adenovirus D is a Human adenovirus D serotype 8, a Human adenovirus D serotype 13, a Human adenovirus D serotype 19, a Human adenovirus D serotype 37, or any combination thereof.
6. The method according to claim 3 , wherein the Human adenovirus E is a Human adenovirus E serotype 4.
7. The method according to claim 1 , wherein administration of the one or more Ranpirnase has an antiviral activity that reduces or suppresses a level of virus or viral titer in an individual.
8. The method according to claim 1 , wherein administration of the one or more Ranpirnase has an antiviral activity that reduces or suppresses viral replication.
9. The method according to claim 1 , wherein administration of the one or more Ranpirnase has an antiviral activity that reduces or suppresses protein synthesis in one or more cells of an individual.
10. The method according to claim 1 , wherein administration of the one or more Ranpirnase has an antiviral activity that reduces or suppresses a level of tRNA in one or more cells of an individual.
11. The method according to claim 1 , wherein the pharmaceutical composition is formulated as an ophthalmic formulation for use in an ophthalmic route of administration.
12. The method according to claim 11 , wherein the pharmaceutical composition further comprises one or more pharmaceutically-acceptable carriers and optionally one or more pharmaceutically-acceptable components.
13. The method according to claim 11 , wherein the ophthalmic formulation is a liquid formulation, a colloidal formulation, a semi-solid formulation or a solid formulation.
14. The method according to claim 11 , wherein the ophthalmic formulation is administered by an ocular instillation, an ocular irrigation, an intraocular injection, an intracorneal injection, intravitreal injection or a subconjunctival injection.
15. The method according to claim 11 , wherein the ophthalmic formulation is a controlled release delivery platform.
16. The method or use according to claim 15 , wherein the controlled release delivery platform is an extended release formulation or a sustained release formulation.
17. The method according to claim 11 , wherein the ophthalmic formulation is an ocular implant, an ophthalmic implant, a punctal plug, an intraocular implant, an intracorneal implant or a subconjunctival implant.
18. The method according to claim 1 , wherein the Ranpirnase has the N-terminus blocked pyroglutamic acid or pyrrolidone carboxylic acid.
19. The method according to claim 1 , wherein the pharmaceutical composition is administered four times a day.
20. The method according to claim 1 , wherein the pharmaceutical composition is administered eight times a day.